Skip to content

Christine Blasey

2 papers in the library · 515 citations · publishing 2018-2026

Papers

Sort Most recent Most cited

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

The American journal of psychiatry June 1, 2026 Jason M Tucciarone, Igor D. Bandeira, Christine Blasey et al. 5 citations

Ketamine rapidly reduces suicidal ideation in major depressive disorder (MDD), but its effects are transient. Preclinical and clinical studies suggest that ketamine's antidepressant and antisuicidal effects may be partly mediated by mu-opioid receptor (MOR) modulation. The authors investigated the efficacy and safety of low-dose sublingual buprenorphine, a partial MOR agonist, as a follow-on...

Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism

American Journal of Psychiatry August 29, 2018 Nolan Williams, Boris D. Heifets, Christine Blasey et al. 510 citations

OBJECTIVE: In addition to N-methyl-d-aspartate receptor antagonism, ketamine produces opioid system activation. The objective of this study was to determine whether opioid receptor antagonism prior to administration of intravenous ketamine attenuates its acute antidepressant or dissociative effects. METHOD: In a proposed double-blind crossover study of 30 adults with treatment-resistant...